Research programme: sublingual allergy immunotherapies - ALK-Abello

Drug Profile

Research programme: sublingual allergy immunotherapies - ALK-Abello

Alternative Names: Cat allergy vaccine; Recombinant allergy vaccine tablets; Tablet-based allergy vaccines - ALK-Abello

Latest Information Update: 08 Jul 2011

Price : $50

At a glance

  • Originator ALK-Abello
  • Class Allergens; Allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Research Hypersensitivity

Most Recent Events

  • 06 Jul 2011 Early research in Hypersensitivity in Denmark (Sublingual)
  • 31 Jan 2007 Preclinical development is ongoing
  • 30 Nov 2005 The programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top